Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,133 questions · 1,153 findings · 36 reviews · Skin

No studies found 407 · 35.3%GRADE not reported 90 · 7.8%Very low 183 · 15.9%Low 209 · 18.1%Moderate 211 · 18.3%High 53 · 4.6%

Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam

Number of participants with any adverse event (primary tolerability outcome) · participants with moderate to severe hand eczema

Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with vehicle foam (moderate certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 30 mg vs placebo

Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).

1 finding from 1 review

Oral retinoids: alitretinoin 10 mg vs placebo

Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema

Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam

Primary: adverse events ‐ any adverse event treatment‐related (application site pruritus) · participants with moderate to severe hand eczema

Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ any adverse event treatment‐related… compared with vehicle foam (moderate certainty).

1 finding from 1 review

Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam

Secondary: reduction in severity, participant‐rated scoring · participants with moderate to severe hand eczema

Corticosteroid creams/ointments: clobetasol propionate foam probably leads to higher secondary: reduction in severity, participant‐rated scoring compared with vehicle foam (moderate certainty).

1 finding from 1 review

Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam

Secondary: reduction in severity, investigator‐rated scoring ‐ improvement at least 2 grades · participants with moderate to severe hand eczema

Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in secondary: reduction in severity, investigator‐rated scoring ‐… compared with vehicle foam (moderate certainty).

1 finding from 1 review

Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week

Primary: investigator‐rated good/excellent control of symptoms · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…

Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with 2 times/week (low certainty).

1 finding from 1 review

Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week

Primary: participant‐rated good/excellent control of symptoms Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroid creams/ointments: mometasone furoate cream 3 times/week vs 2 times/week

Primary outcome 3: Adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…

Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: adverse events compared with 2 times/week (low certainty).

1 finding from 1 review

Oral methotrexate and oral prednisone vs prednisone or placebo

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).

1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review